Pharma BD Deal Intelligence
Still a slow-burn discovery bet: AbbVie's GPCR neuroscience deal with Sosei Heptares, $40M upfront against up to $1.2B in milestones, has hit three $10M research milestones through April 2026, but AbbVie has yet to exercise any of its three program options.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AbbVie is paying Japan's Sosei Heptares up to $1.28 billion to collaborate on small-molecule drugs targeting G protein-coupled receptors for neurological…
AbbVie and Sosei Heptares today said they will collaborate to discover, develop, and commercialize novel small molecules modulating novel GPCR targets in…
Nxera Pharma (formerly Sosei Heptares) to receive a US$10M milestone payment from AbbVie on achieving the THIRD research milestone in the 2022 multi-target…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Sosei Heptares and AbbVie entered a drug discovery collaboration and option-to-license agreement to develop small molecules modulating novel GPCR targets in neurological disease. Sosei received $40M upfront, up to $40M in near-term research milestones, and up to $1.2B in option/development/commercial milestones plus royalties; AbbVie has options on up to three programs. As of April 2026 the collaboration remained in the discovery/research phase and was progressing on plan: three US$10M research milestones had been achieved (first June 2024, second September 2025, third April 2026), totaling $30M of the up-to-$40M near-term research pool. AbbVie had not yet exercised any of its program license options. Sosei Heptares has since rebranded as Nxera Pharma.
6.5M US cases/yr · $120.0B Global CNS therapeutics market 2023 · ~34% Share of FDA-approved drugs targeting GPCRs
Neurological disease is AbbVie's single largest franchise after immunology, anchored by Vraylar (cariprazine) in schizophrenia/bipolar/MDD adjunct and migraine assets Qulipta (atogepant) and Ubrelvy (ubrogepant) acquired via Allergan. The broader CNS opportunity AbbVie is accessing via Sosei Heptares' GPCR platform spans neurodegeneration (Alzheimer's ~6.5M U.S. prevalent cases, Parkinson's ~1M U.S. prevalent cases), psychiatric disorders (schizophrenia ~3.5M U.S. prevalent, depression ~21M U.S. annual), and orphan CNS indications where GPCR modulation historically underpins validated franchises. GPCRs account for roughly one-third of all approved drugs, but novel allosteric and biased agonist chemistries have remained elusive for CNS targets due to blood-brain barrier penetration and subtype selectivity constraints — Sosei Heptares' StaR (Stabilized Receptor) platform is the leading structural biology approach to solving that problem. AbbVie's commercial capability in psychiatry (Vraylar >$2.8B 2023 sales) and neurology creates a credible path for any asset option-exercised under the collaboration to enter a built-out specialty CNS commercial footprint.
The CNS GPCR competitive landscape splits into established symptomatic franchises and platform-driven discovery plays. Vraylar (cariprazine, AbbVie) D2/D3 partial agonist and Rexulti (brexpiprazole, Otsuka/Lundbeck) set the antipsychotic benchmark. Cobenfy (xanomeline-trospium, Bristol Myers Squibb via Karuna acquisition $14B) validated M1/M4 muscarinic agonism as a non-dopaminergic schizophrenia approach — the most direct GPCR precedent motivating AbbVie's Sosei bet. Migraine CGRP receptor antagonists include Qulipta (atogepant, AbbVie), Nurtec ODT (rimegepant, Pfizer/Biohaven), and Ubrelvy (ubrogepant, AbbVie). GLP-1 agonists (Wegovy/semaglutide, Novo Nordisk; Zepbound/tirzepatide, Lilly) are generating CNS read-across interest in neurodegeneration. Platform competitors to Sosei Heptares' StaR include Domain Therapeutics (biased GPCR agonists), Confo Therapeutics (Nanobody-stabilized GPCRs, Roche partnership), and Septerna (public 2024). AbbVie's option on up to three programs gives it preferential shots at whichever targets de-risk fastest from the Sosei platform.
First research milestone achieved under the AbbVie GPCR neurological-disease collaboration (per Nxera Pharma April 2026 milestone release).
Second research milestone achieved under the AbbVie GPCR neurological-disease collaboration (per Nxera Pharma April 2026 milestone release).
Nxera Pharma achieved the third research milestone under its 2022 AbbVie GPCR neurological-disease collaboration, triggering a US$10M payment. Three of the up-to-$40M near-term research milestones ($30M total) now earned; no license option exercised yet.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Sosei Group Corp. (Sosei Heptares) (this deal) | 2022 | $1.3B | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2022 deals · AbbVie Inc. deals · Neurology deals